5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Janssen, Wiebke ^a,b   Schymura, Yves ^c   Novoyatleva, Tatyana ^a,b   Kojonazarov, Baktybek ^a,b   Boehm, Mario ^a,b   Wietelmann, Astrid ^c   Luitel, Himal ^a,b   Murmann, Kirsten ^a,b   Krompiec, Damian Richard ^a,b   Tretyn, Aleksandra ^c   Pullamsetti, Soni Savai ^c   Weissmann, Norbert ^a,b   Seeger, Werner ^a,b,c   Ghofrani, Hossein Ardeschir ^a,b   Schermuly, Ralph Theo ^a,b  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b German Center for Lung Research   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; PLACEBO; SB 204741; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; TERGURIDE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; PROTECTIVE AGENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG MECHANISM; FIBROBLAST; HEART CATHETERIZATION; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE OVERLOAD; IN VITRO STUDY; LUNG ARTERY BANDING; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CHEMISTRY; DRUG EFFECTS; ENDOMYOCARDIAL FIBROSIS; GENETICS; HEART; HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEMODYNAMICS; METABOLISM;

MUS;

ANIMALS; ENDOMYOCARDIAL FIBROSIS; HEART; HEART FAILURE; HEMODYNAMICS; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; PROTECTIVE AGENTS; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84947648693     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/438403     Document Type: Article

References (37)

1. N. F. Voelkel, R. A. Quaife, L. A. Leinwand et al., "Right ventricular function and failure: report of a National Heart, Lung, and Blood Instituteworking group on cellular andmolecular mechanisms of right heart failure," Circulation, vol. 114, no. 17, pp. 1883-1891, 2006.
2. H. J. Bogaard, K. Abe, A. V. Noordegmaf, and N. F. Voelkel, "The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension," Chest, vol. 135, no. 3, pp. 794-804, 2009.
3. M. Guglin and S. Verma, "Right side of heart failure," Heart Failure Reviews, vol. 17, no. 3, pp. 511-527, 2012.
4. D. A. Mann and F. Oakley, "Serotonin paracrine signaling in tissue fibrosis," Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1832, no. 7, pp. 905-910, 2013.
5. K.-G. Shyu, "Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure?" Circulation Research, vol. 104, pp. 1-3, 2009.
6. O. Lairez, T. Cognet, S. Schaak et al., "Role of serotonin 5- HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice," Journal ofNeural Transmission, vol. 120, no. 6, pp. 927-935, 2013.
7. C. G. Nebigil, D.-S. Choi, A. Dierich et al., "Serotonin 2B receptor is required for heart development," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 17, pp. 9508-9513, 2000.
8. C. G. Nebigil, P. Hickel, N. Messaddeq et al., "Ablation of serotonin 5-HT2B receptors in mice leads to abnormal cardiac structure and function," Circulation, vol. 103, no. 24, pp. 2973-2979, 2001.
9. F. Jaffré, J. Callebert, A. Sarre et al., "Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1β, and tumor necrosis factor-α cytokine production by ventricular fibroblasts," Circulation, vol. 110, no. 8, pp. 969-974, 2004.
10. L. Monassier, M.-A. Laplante, F. Jaffré, P. Bousquet, L. Maroteaux, and J. de Champlain, "Serotonin 5-HT2B receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice," Hypertension, vol. 52, no. 2, pp. 301-307, 2008.
11. F. Jaffré, P. Bonnin, J. Callebert et al., "Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergicdependent cardiac hypertrophy," Circulation Research, vol. 104, no. 1, pp. 113-123, 2009.
12. L. Abenhaim, Y. Moride, F. Brenot et al., "Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group," The New England Journal of Medicine, vol. 335, pp. 609-619, 1996.
13. D. Kosanovic and R. Schermuly, "Are tyrosine kinase inhibitors the better serotonin inhibitors?" American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 1, pp. 4-5, 2013.
14. M. Thomas, L. Ciuclan, M. J. Hussey, and N. J. Press, "Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension," Pharmacology and Therapeutics, vol. 138, no. 3, pp. 409-417, 2013.
15. Y. Liu, H.-Y. Tian, X.-L. Yan, F.-L. Fan, W.-P. Wang, and J.-L. Han, "Serotonin inhibits apoptosis of pulmonary artery smooth muscle cells through 5-HT2A receptors involved in the pulmonary artery remodeling of pulmonary artery hypertension," Experimental Lung Research, vol. 39, no. 2, pp. 70-79, 2013.
16. L. Ciuclan, M. J. Hussey, V. Burton et al., "Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression," The American Journal of Respiratory and Critical CareMedicine, vol. 187, no. 1, pp. 78-89, 2013.
17. T. Novoyatleva, Y. Schymura, W. Janssen et al., "Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction," Basic Research in Cardiology, vol. 108, no. 2, article 325, 2013.
18. M. M. Budev, A. C. Arroliga, H. P. Wiedemann, and R. A. Matthay, "Cor pulmonale: an overview," Seminars in Respiratory and Critical Care Medicine, vol. 24, no. 3, pp. 233-243, 2003.
19. L. R. Frumkin, "The pharmacological treatment of pulmonary arterial hypertension," Pharmacological Reviews, vol. 64, no. 3, pp. 583-620, 2012.
20. H.-A. Ghofrani, N. Galiè, F. Grimminger et al., "Riociguat for the treatment of pulmonary arterial hypertension," The New England Journal of Medicine, vol. 369, no. 4, pp. 330-340, 2013.
21. C. E. Ventetuolo and J. R. Klinger, "WHO Group 1 pulmonary arterial hypertension: current and investigative therapies," Progress in Cardiovascular Diseases, vol. 55, no. 2, pp. 89-103, 2012.
22. S. Schäfer, P. Ellinghaus, W. Janssen et al., "Chronic inhibition of phosphodiesterase 5 does not prevent pressureoverload- induced right-ventricular remodelling," Cardiovascular Research, vol. 82, no. 1, pp. 30-39, 2009.
23. P. Herve, L. Drouet, C. Dosquet et al., "Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin," The American Journal of Medicine, vol. 89, no. 1, pp. 117-120, 1990.
24. P. Hervé, J.-M. Launay, M.-L. Scrobohaci et al., "Increased plasma serotonin in primary pulmonary hypertension," The American Journal of Medicine, vol. 99, no. 3, pp. 249-254, 1995.
25. M. Humbert, P. Labrune, O. Sitbon et al., "Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis," European Respiratory Journal, vol. 20, no. 1, pp. 59-65, 2002.
26. A. Kéreveur, J. Callebert, M. Humbert et al., "High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (Prostacyclin) therapy," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 10, pp. 2233-2239, 2000.
27. R. Dumitrascu, C. Kulcke, M. Königshoff et al., "Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats," European Respiratory Journal, vol. 37, no. 5, pp. 1104-1118, 2011.
28. J.-M. Launay, P. Hervé, K. Peoc'h et al., "Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension," Nature Medicine, vol. 8, no. 10, pp. 1129-1135, 2002.
29. E. Hironaka, M. Hongo, A. Sakai et al., "Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats," Cardiovascular Research, vol. 60, no. 3, pp. 692-699, 2003.
30. Y. Kanai, S. Hori, T. Tanaka et al., "Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats," Cardiovascular Research, vol. 27, no. 9, pp. 1619-1623, 1993.
31. M. Miyata, M. Ito, T. Sasajima, H. Ohira, Y. Sato, and R. Kasukawa, "Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist," Lung, vol. 178, no. 2, pp. 63-73, 2000.
32. S. Jähnichen, R. Horowski, and H. H. Pertz, "Agonism at 5-HT2B receptors is not a class effect of the ergolines," European Journal of Pharmacology, vol. 513, no. 3, pp. 225-228, 2005.
33. B. Kojonazarov, H. Luitel, A. Sydykov et al., "The peroxisome proliferator-activated receptor β/δ agonist GW0742 has direct protective effects on right heart hypertrophy," Pulmonary Circulation, vol. 3, no. 4, pp. 926-935, 2013.
34. P. R. Buskohl, M. L. Sun, R. P. Thompson, and J. T. Butcher, "Serotonin potentiates transforming growth factorbeta3 induced biomechanical remodeling in avian embryonic atrioventricular valves," PLoS ONE, vol. 7, no. 8, Article ID e42527, 2012.
35. V. Kren, E. Eich, and H. H. Pertz, "Pergolide, terguride and N, N'-spacerlinked oligomers of both interact with 5-HT2A receptors of rat tail artery," Physiological Research, vol. 53, pp.35-43, 2004.
36. F. Jantschak, J. Brosda, R. T. Franke et al., "Pharmacological profile of 2-bromoterguride at human dopamine D 2, porcine serotonin 5-hydroxytryptamine 2A, and α 2C-adrenergic receptors, and its antipsychotic-like effects in rats," Journal of Pharmacology and Experimental Therapeutics, vol. 347, no. 1, pp. 57-68, 2013.
37. E. Ciccarelli and F. Camanni, "Diagnosis and drug therapy of prolactinoma," Drugs, vol. 51, no. 6, pp. 954-965, 1996.